Antiretroviral therapy-associated dyslipidemia in patients from a reference center in Brazil.

Submitted by Karine Ribeiro (karinelg.ribeiro@gmail.com) on 2014-10-30T20:06:48Z No. of bitstreams: 1 ARTIGO_AntiretroviralTherapyAssociated.pdf: 398127 bytes, checksum: 73d8a42ed56a34b0eaff8ebb9ef9f84c (MD5)Approved for entry into archive by Gracilene Carvalho (gracilene@sisbin.ufop.br) on 2014-11-11T20:13:15Z (GMT) No. of bitstreams: 1 ARTIGO_AntiretroviralTherapyAssociated.pdf: 398127 bytes, checksum: 73d8a42ed56a34b0eaff8ebb9ef9f84c (MD5)Made available in DSpace on 2014-11-11T20:13:15Z (GMT). No. of bitstreams: 1 ARTIGO_AntiretroviralTherapyAssociated.pdf: 398127 bytes, checksum: 73d8a42ed56a34b0eaff8ebb9ef9f84c (MD5) Previous issue date: 2011The aim of this study was to determine the impact of antiretroviral therapy on the lipid profile of human immunodeficiency virus (HIV) patients before and after the initiation of highly active antiretroviral therapy (HAART). This was a cross-sectional analysis of patients receiving HAART at a reference center in Belo Horizonte, Brazil, on the basis of medical records from 2002 to 2006. Patients were included if they had at least one lipid test or a clinical or laboratory diagnosis of dyslipidemia/lipodystrophy. Among the 692 patients, 620 met the eligibility criteria. The majority were males (66.5%), middle age (average 39 years), had a low educational level (60.4%), and low income (51.0%). HAART duration ranged from 11 days to 4.6 years, with a mean of 28.6 months (SD = ± 470.19 days). The prevalence of dyslipidemia/lipodystrophy nearly tripled (11.3% pre- and 32.4% post-HAART). Dyslipidemia was associated with older age (P = 0.007), nucleoside reverse transcriptase inhibitor (NRTI) + protease inhibitor (PI) regimens (P = 0.04), NRTI + non-NRTI (NNRTI) regimens (P = 0.026), the use of stavudine (d4T) in any regimen (P = 0.002) or in NRTI-based regimens (P = 0.006), and longer exposure to HAART (P < 0.000). In addition, there was no correlation between dyslipidemia and gender (P = 0.084). Only 2.0% of the patients received treatment for dyslipidemia during the trial. These results= show a need for continuous monitoring of patients under antiretroviral therapy, particularly those using NRTI-based regimens, especially when combined with d4T and PIs. Secondly, interventions should be developed to correct metabolic changes